Where Can I Get More Information About Lyme Disease And Lyme Disease Vaccine
The risk of acquiring Lyme disease, even in endemic areas of the United States, is very localized . The most up-to-date information about areas of risk can be obtained from local public health authorities. Detailed American recommendations for the use of Lyme disease vaccine have been published in the Morbidity and Mortality Weekly Report Canadian guidelines from the National Advisory Committee on Immunization will be published soon in the Canada Communicable Disease Report. The product monograph should be consulted for specific prescribing information.
What Are Symptoms Of Lyme Disease
Lyme disease symptoms can often be mistaken for the flu. Within the first three to 30 days after a tick bite, a person can experience fever, chills, headache, swollen lymph nodes, muscle aches and fatigue.
A rash at the site of the tick bite can occur in about 70 to 80 per cent of infections, on average a week after infection. The rash can grow up to 12 inches in size and may feel warm or hot to the touch.
Days to months after infection, symptoms can progress to include a severe headache, neck stiffness, additional rashes may develop on other areas of the body.
Facial palsy, arthritis, nerve pain, dizziness, heart palpitations, shooting pains or tingling in the hands or feet as well as problem with short-term memory.
Is A Vaccine Possible Again
There are no vaccines available to prevent Lyme disease today in humans, and it seems unlikely that one will appear anytime soon. Theres a lot of hurdles to overcome not just regulatory hurdles, but public acceptance as well. Any pharmaceutical company will likely assess the risk of producing a new vaccine carefully, given its history and the persistent but unfounded belief that the vaccine was harmful. But given the growing incidence and regional spread of Lyme disease in North America, and a greater understanding of the harms it can cause, there is arguably a greater need for a vaccine today than ever before. And given we can vaccinate dogs against Lyme, perhaps we should be cautiously optimistic that the continued search for a vaccine may lead to its reappearance someday.
Also Check: Treating Lyme Disease With Chemotherapy
The Gathering Storm: The Fda Meets
With lawsuits pending and questions from the public and the media, and facing an increasingly complex and explosive situation, the FDA reconvened its advisory panel on 31 January 2001 to discuss the future of the Lyme vaccine. The participants included the FDA scientific advisors, the LYMErix manufacturer, independent experts, practising physicians, the vaccine victims and their lawyers.
This panel, described by one participant as raucous and riotous , provided a forum for all of the stakeholders . In support of the vaccine, the FDA summarized the VAERS data and concluded that the evidence did not support a causative association. The vaccine manufacturer, now GlaxoSmithKline following a corporate merger, assured the assembled parties that the LYMErix vaccine did not cause harm to its recipients. They reviewed the status of their phase IV post-marketing surveillance. Practising physicians spoke of vaccine efficacy by describing the dramatic reduction in Lyme disease cases in their own practices.
Others raised concerns about the vaccine’s safety. Scientists argued a potential role for genetic susceptibility and OspA-related autoimmunity in vaccine complications. Poignant presentations by several vaccine victims described in detail their suffering. The prosecuting lawyers for the largest class action suit claimed that manufacturers suppressed reports of adverse events from the licensing trial and provided inadequate warnings to genetically susceptible individuals.
Four Safe And Effective Vaccines
Compared to humans, dogs are lucky. There are currently 4 extremely safe, effective, and reliable vaccines7-9 on the market that have all been through the United States Drug Administration licensing requirements for safety, efficacy, purity, and potency.
All available canine Lyme disease vaccines produce borreliacidal antibodies in the dog in response to vaccinal outer surface protein A . These antibodies work in the ticks gut to bind the bacteria during the blood meal, sterilizing the gut of the tick and preventing transmission of bacteria into the dog.
OspC is the main immunogenic protein exhibited by Borrelia in the ticks salivary glands and in the dogs body during natural infection. Three of the current Lyme disease vaccines contain 2 strains of inactivated Borrelia isolates1 OspA producing strain and 1 unique OspC producing strain, which perhaps adds an additional layer of protection.
Read Also: Lyme Disease In Horses Treatment
Vaccine Licensure Recommendation And Initial Use
In response to growing reports of Lyme disease cases in the United States from 1982 to 1996, the number of reported cases increased by 32 times SmithKline Beecham developed LYMERix, which was licensed in 1998. The licensed product was a recombinant vaccine containing an outer surface protein from theBorrelia burgdorferi bacteria. Before licensure, 6,478 people received 18,047 doses of the vaccine during clinical testing. The most common adverse events noted within 30 days of receiving at least one dose of the vaccine included pain or reaction at the injection site, joint pain, muscle pain, and headache. Of these, only pain and reactions at the injection site occurred much more frequently in the vaccine recipients than in those who received a placebo.
The efficacy trial for the vaccine showed that it was 78% effective in preventing Lyme disease after all three doses were given. It was also shown to be 100% effective at preventing asymptomatic cases, where an individual would get the disease and develop antibodies against it but never develop any symptoms.
Based on the clinical trial data, the vaccine was given a permissive recommendation by the Advisory Committee on Immunization Practices. A permissive recommendation means a vaccine is not added to the childhood or adult immunization schedules, like vaccines against common childhood diseases . Instead, the vaccine is considered for use only in individuals or groups with specific risk factors for a disease.
Combating Concerns About Vaccination
There are still some who believe that Lyme disease is not a disease worth vaccinating against or the vaccine causes more harm than good. This is despite the:
- Extremely large number of clinical Lyme disease cases and nonclinical Lyme infections seen in small animal practice in endemic areas in the U.S., including the often fatal syndrome of Lyme nephritis
- Millions of dogs that receive Lyme disease vaccines annually with no data to suggest any resulting harm from the vaccine.
Don’t Miss: What Are The Lasting Effects Of Lyme Disease
How Many Doses Of Vaccine Are Needed Is A Booster Necessary
Three doses of Lyme disease vaccine are required to provide optimal protection. The first two doses should be timed so that maximal protection immediately precedes the beginning of the tick’s nymphal stage feeding season . This ensures that the third dose at 12 months immediately precedes the subsequent tick season. It is not known yet whether additional booster doses will be required for subsequent seasons.
Covid Vaccination Side Effects
Those who were vaccinated reported similar side effects as the general population.
In fact, MyLymeData participants reported slighter lower rates of COVID vaccination side effects than those reported by the general population. It is not clear whether these differences are meaningful, however.
Although the percentage of specified COVID vaccination side effects was lower in the MyLymeData respondents than with the general public, some patients reported Lyme flare- ups . It is possible that patients reporting Lyme flare-ups misattributed COVID vaccination side effects to Lyme disease since many of the symptoms overlap.
Also Check: Early Signs Of Lyme Disease In Child
Is Lyme Disease Vaccine Effective
LYMErix was compared with placebo in an endemic area in 10,936 healthy individuals who were given three doses of the vaccine at 0 months, one month and 12 months . In the year after two doses of vaccine were given, symptomatic, laboratory-confirmed Lyme disease occurred in 22 LYMErix recipients and 43 placebo recipients . After the third dose was administered at 12 months, Lyme disease was diagnosed in 16 vaccine recipients and 66 placebo recipients giving a vaccine efficacy of 76% .
Valneva And Pfizer Start New Phase 2 Study For Lyme Disease Vaccine Candidate
Related tags:Valneva, Pfizer, Vaccine
The study builds on previous Phase 2 studies: incorporating new dose regimens and now including children aged 5-17 years old. It will determine whether the candidate proceeds to Phase 3 studies.
Kathrin Jansen, Senior Vice President and Head of Pfizer Vaccine Research and Development, said: We hope this Phase 2 trial, with a simplified schedule, will provide evidence that the investigational vaccine can be used in populations that are at risk of contracting Lyme disease, potentially including children age five years and older.
Lyme disease is a systemic infection caused by Borrelia bacteria burgdorferi sensu lato transmitted to humans by infected Ixodes ticks4. It is considered the most common vector borne illness in the Northern Hemisphere. According to the U.S. Centers for Disease Control and Prevention , approximately 476,000 Americans are diagnosed and treated for Lyme disease each year with at least a further 200,000 cases in Europe.
The effects of climate change such as warmer winters – means that ticks are spreading to new areas and the medical need for vaccination is steadily increasing, note the companies.
Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop the multivalent protein subunit candidate VLA15. The program had previously been granted Fast Track designation by the US FDA in July 2017.
Also Check: What Are The After Effects Of Lyme Disease
Lyme Disease Is Dangerous For Us And A Tragedy For The Bacteria
Lyme disease is caused by a bite from a deer tick, also known as black-legged ticks or Ixodes scapularis. The tick attaches by jamming a barb-lined spear into your skin, gluing itself in place with a sticky substance, and injecting a fluid into the wound that prevents the blood from clotting. Thats gross, but its not health-endangering.
The problem is when the parasite has itself been parasitized by a spiral-shaped bacteria called Borrelia burgdorferi or one of its closely-related cousins. As the tick slurps up your blood, bacteria make their way from its gut to its salivary glands and then into your body.
For the Borrelia, this is a terrible tragedy. The bacteria was hoping to find itself was inside the body of one of its natural hosts: a mouse, bird or deer. It has evolved to live inside these animals as a harmless passenger. Through evolution, parasites come to an agreement with their hosts that they wont harm each other, says Sam Telford, a professor of epidemiology at the Tufts Cummings School of Veterinary Medicine whos a leading expert on Lyme disease.
When a host animal is bitten by another tick, the bacteria will move on, and the endless dance will continue. But humans are a dead end: its unlikely that any human suffering the deeply uncomfortable effects of Borrellia infection will be wandering around in a woodsy habitat where it might get reparasitized by another tick. So as nasty as Lyme disease is for us, for the Borrelia, its the end of the road.
What Happened To The Lyme Disease Vaccine
Q: When I contracted Lyme disease, my doctor diagnosed it early and treated me within days with doxycycline.
I once read that a vaccine for Lyme disease was available at one point. Because the source was online, Im not sure it was reliable.
Is it true that there was once a vaccine? And is it also true that it just wasnt cost-effective to produce, as it would only be used by a small portion of the population?
A: If you had a dog and lived where deer ticks are widespread, your veterinarian could offer a Lyme disease vaccine for your canine companion. Sadly, though, there is no human vaccine available.
The Food and Drug Administration approved LYMErix in 1998 to protect people from infection with the microbe that causes Lyme disease . Three shots provided 76% protection .
Questions about vaccine safety at that time created tremendous controversy, not unlike today. Some people who developed arthritis following vaccination sued the drug company. Although the FDA concluded that the benefits far outweighed the risks, negative publicity resulted in very few people requesting the shot. As a result, in 2002 the manufacturer withdrew it.
Q: Lately Ive been struck by two different TV commercials for Dupixent to treat asthma and eczema. Can you elaborate on how one medication could be advertised to treat these two completely different conditions?
A: Dupilumab is a biologic injectable drug. The mab at the end of the generic name stands for monoclonal antibody.
Read Also: How Do They Treat Lyme Disease In Humans
Where Are We Now
As Julia Belluz reported at Vox, Lyme cases doubled since 1991, spread by an increased number of infected ticks. Its now the most common vector-borne disease in the United States. And climate change seems to be partly to blame: As temperatures warm, a greater proportion of the US becomes hospitable to the ticks. Overall, vector-spread diseases like chikungunya, Zika, and West Nile are spreading faster than ever.
A safe and effective Lyme vaccine is desperately needed, Lise Nigrovic, a pediatric Lyme disease researcher at Boston Childrens Hospital, says in an email. Yet if you wanted to protect yourself with a Lyme disease vaccine, you couldnt get one. As Belluz explained, prevention efforts currently focus on avoiding tick bites. That means covering up exposed skin when spending time in wooded areas, using insect repellent, and checking your body for ticks after youve spent time outdoors in tick-laden areas.
WBUR in Boston reports there have been some small efforts to revive LYMErix , but the pharmaceutical industry has lost interest in it, and grassroots efforts have gone unfunded. The Lyme vaccine for dogs works in a similar manner to LYMErix. But while it does help control the spread of the disease, it doesnt make up for the lack of a vaccine in humans.
The loss of LYMErix represents the loss of a powerful tool for Lyme disease prevention, the authors of the Epidemiology and Infection article state.
Theres A Vaccine For Lyme Disease So Why Cant We Get It
Thanks to vaccines, the number of COVID-19 cases has plummeted in the U.S. and restrictions are being lifted across the country. But as we return to our normal activities, we face a more familiar summertime scourge. Were in the thick of Lyme disease season the two-month run from early June to the end of July when 85 percent of infections take place. Surprisingly, vaccines may have allowed us to avoid this epidemic, too. As I learned during my own recent bout with Lyme disease, a vaccine has existed for decades, but its no longer available.
Its yet another frustrating aspect of this mysterious disease. One bite from a tiny, hard-to-detect tick can lead to a host of odd symptoms, including arthritis, serious cardiac issues, and neurological damage in the most severe cases. The disease is easy to treat once you get a diagnosis, but that can be elusive. And while work is underway to develop a new and better vaccine, it may take years to come to market. Heres what we know about how the disease works, and what you can do to stay safe.
Recommended Reading: Western Blot Assay For Lyme Disease
No Lyme Vaccine Yet But Antibody Shot Could Provide Seasonal Immunity
Lyme disease has become an insidious epidemic in the United States. Caused by bacteria transmitted through the bite of an infected tick, it can lead to heart problems, meningitis or arthritis if left untreated. It is the most common tick-borne illness in the United States, and the Centers for Disease Control and Prevention estimates that around 475,000 people likely contract the disease each year.
Scientists, doctors and ecologists have worked for decades to slow the spread of Lyme and the blacklegged, or deer, ticks that carry the disease-causing bacteria. However, the ticks range continues to expand. Today, over 50% of the American population lives in an area where these ticks are found.
The U.S. Food and Drug Administration approved a vaccine against Lyme in 1998, but it was met by controversy and was pulled from the market three years later. Efforts continue today to create a human vaccine as well as to stop the spread of Lyme by other means, including using gene editing to immunize mice that can transmit the bacteria to ticks, killing deer and using pesticides to control ticks.
In February 2021, we received approval from the FDA to proceed with the first human clinical trial of Lyme PrEP, and all of the volunteers in this trial have been enrolled and received the shot. Our goal for this study, also known as the phase 1 clinical trial, is to test the safety of the new medicine and determine how long it might stay in the bloodstream and prevent Lyme disease.
A New Vaccine And Shot Are Both In Clinical Trials One Is Targeted For Release In 2024
The COVID-19 pandemic boosted the national conversation surrounding vaccines, which is helpful to those who have been working on a medicinal shot and vaccine to prevent Lyme disease.
At a time when all the talk seems to be about vaccinations for COVID-19, new chatter is building around a new vaccine and shot in development that would immediately block the transmission of Lyme disease from an infected tick to humans.
New York has the third-highest cases of Lyme disease infections, behind Pennsylvania and New Jersey. According to the CDC, New York had 2,446 confirmed cases in 2018, the most recent data released, and 1,192 probable cases of Lyme, which has historically been underreported.
There actually was a Lyme vaccine for humans on the market once before. LYMErix was created in the late 1990s and early 2000s, which prevented 76 and 92 percent of infections after three injections, according to the National Institute of Allergy and Infectious Diseases. But there wasnt strong public interest in a Lyme disease vaccine at the time, and production ultimately came to a halt because sales declined from 1.5 million doses in 1999 to an estimated 10,000 doses in 2002.
Although Lyme disease cases were on the rise then, LYMErix debuted near the beginning of anti-vaccine mania, Vox reported, which contributed to the vaccine’s poor sales performance.
Recommended Reading: What Does Lyme Disease Rash Look Like